Diane-35 Articles
Benefits of Diane 35 and generics outweigh risks in specific patient group, says EMA unit; other actions
17 May 2013
EMA to review third- and fourth-generation combined OCs; France investigates Diane-35
29 January 2013
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
